belongs to the macrophage mannose receptor family of C-type lectin endocytic receptors and behaves as an antigen uptake/processing receptor for dendritic cells (DC). To investigate DEC-205 tissue distribution in human leukocytes, we generated a series of anti-human DEC-205 monoclonal antibodies (MMRI-5, 6 and 7), which recognized epitopes within the C-type lectin-like domains 1 and 2, and the MMRI-7 immunoprecipitated a single~200 kDa band, identified as DEC-205 by mass spectrometry. MMRI-7 and another DEC-205 mAb (MG38), which recognized the epitope within the DEC-205 cysteine-rich and fibronectin type II domain, were used to examine DEC-205 expression by human leukocytes. Unlike mouse DEC-205, which is reported to have predominant expression on DC, human DEC-205 was detected by flow cytometry at relatively high levels on myeloid blood DC and monocytes, at moderate levels on B lymphocytes and at low levels on NK cells, plasmacytoid blood DC and T lymphocytes. MMRI-7 F(ab9) 2 also labeled monocytes, B lymphocytes and NK cells similarly excluding reactivity due to non-specific binding of the mAb to FccR. Tonsil mononuclear cells showed a similar distribution of DEC-205 staining on the leukocytes. DEC-205-specific semiquantitative immunoprecipitation/western blot and quantitative reverse transcriptase-PCR analysis established that these leukocyte populations expressed DEC-205 protein and the cognate mRNA. Thus, human DEC-205 is expressed on more leukocyte populations than that were previously assumed based on mouse DEC-205 tissue localization studies. The broader DEC-205 tissue expression in man is relevant to clinical DC targeting strategies and DEC-205 functional studies.
Introduction
Dendritic cells (DC) are specialized antigen presenting cells with unique capacities for migrating, antigen uptake/processing and presenting to T cells, and stimulating and activating B and NK cells (1, 2) . DC are equipped with an array of C-type lectin receptors, including classical [Ca 2+ -dependent sugar binding proteins, e.g. DC-SIGN, macrophage mannose receptor (MMR)] and non-classical C-type lectins (e.g. b-glucan receptor), which appear to play major roles in both innate and adaptive immunity (3, 4) . DEC-205 (CD205) is a putative antigen uptake and processing receptor, cloned first in mouse (5) . The anti-mouse DEC-205 mAb NLDC-145 stains interdigitating DC, Langerhans cells and thymic epithelia (6) , and has become a ''gold standard'' DC marker for mouse DC research and has been used extensively to localize mouse DC in tissues and to phenotype mouse DC subsets. The mouse DEC-205 cDNA analysis revealed that DEC-205 belongs to a family of type I transmembrane multilectin receptors, including the MMR (7, 8) , phospholipase A 2 receptor (PLA 2 R) (9) and recently described Endo180 (10) . The extracellular domain of these molecules contains a cysteine-rich domain (CR), a fibronectin type II domain (FN) and multiple C-type lectin-like domains (CTLD; 8 for MMR, PLA 2 R and Endo180, and 10 for DEC-205). The relatively short cytoplasmic domains (CP) contain motifs for Tyr-and/or di-hydrophobic amino acid-based endocytosis (11) . We and others cloned human DEC-205, which exhibits 80% protein identity to the mouse homolog (12, 13) , suggesting that its function is conserved between species. The ligand specificity for DEC-205 has not been established, nor has function on thymic epithelia been described, though it was suggested recently that DEC-205 plays a role in clearance of apoptotic thymocytes by thymic epithelial cells (14) .
Recently Mahnke et al. showed that DEC-205 CP contains a cluster of acidic amino acids (an acidic triad, EDE in one letter amino acid code), which mediates efficient transportation of endocytosed DEC-205 to late endosomes/MHC class II compartments. When compared with MMR CP, which lacks an acidic triad, DEC-205 CP increased antigen processing and presentation to CD4 + T lymphocytes by artificial antigen presenting cells 100-fold (15) . More recent publications indicated that NLDC-145 genetically or chemically conjugated to test antigens could target DC in vivo, and elicit antigen-specific CD4 + and CD8 + T lymphocyte responses when injected into mice (11, (16) (17) (18) . Depending on the presence or absence of an additional activation signal (i.e. CD40 agonist), it resulted in either immunostimulatory or immunoregulatory effects, respectively. Therefore, DEC-205 is a very attractive target for therapeutic antigen delivery and this possibility prompted further studies on human DEC-205 tissue distribution and function.
We produced the DEC-205 mAb MMRI-5, 6 and 7, which recognized human DEC-205 specifically. Using the MMRI-7 and the independently derived DEC-205 mAb MG38 for staining and quantitative reverse transcriptase (RT)-PCR, we undertook a comprehensive analysis of DEC-205 expression on human leukocytes. Unexpectedly, we discovered that human DEC-205 is present at various levels on more leukocyte populations than anticipated.
Methods

Cell lines, antibodies and other reagents
Hodgkin's Reed-Sternberg (HRS) cell line L428 was provided by V. Diehl (Klinik fur Innere Medizin, Cologne, Germany) (19) . The other HRS cell line KM-H2 (20) was obtained from the German Collection of Microorganism and Cell Culture (Braunschweig, Germany). Mouse myeloma cell line NS-1 and COS-7 cells were from American Tissue Culture Collection (Manassas, VA, USA). The L428 and KM-H2 cell lines were maintained in RPMI 1640 (Invitrogen, Melbourne, VIC, Australia), 10% FCS (Invitrogen), 100 U ml ÿ1 penicillin and 100 lg ml ÿ1 streptomycin at 37°C in a humidified incubator with 5% CO 2 -95% air. COS-7 cells were maintained in DMEM (Invitrogen), 10% FCS with antibiotics as above.
Unconjugated mAbs against CD3 (PS1), CD14 (RMO52), CD19 (J4.119), CD20 (B9E9), CD56 (N901), PE-conjugated mAb against CD40 (MAB89) and CD235a/glycophorin A (11E4B-7-6) were purchased from Beckman Coulter Immunotech (Gladesville, NSW, Australia). FITC-or PE-conjugated mAb against CD3 (SK7), CD4 (SK3), CD14 (MoP9), CD16 (B73.1), CD19 (SJ25C) and CD20 (L27), allophycocyanin (APC)-conjugated CD11c (S-HCL-3), peridinin chlorophyll protein (PerCP)-conjugated HLA-DR (L243), isotype controls and PE-conjugated streptavidin were purchased from BD Bioscience (Sydney, NSW, Australia (22) .
ELISA plates (Maxisorb) were from Nalge Nunc International (Rochester, NY, USA). Prestained protein standards were from Fermentas (Hanover, MD, USA) or Bio-Rad (Regents Park, NSW, Australia). Molecular biological enzymes (e.g. restriction enzymes, polymerases and ligase) were obtained from Invitrogen, Promega (Sydney, NSW, Australia) or Roche Applied Science (Castle Hill, NSW, Australia). Unless specified, general chemicals were obtained from Sigma or BDH (Poole, England).
Production of DEC-205-Ig fusion proteins
The production of DEC-205 CR/FN-Ig was described previously (23) . To express the DEC-205 internal domains (CTLD1-10) lacking signal peptides as Ig fusion proteins, a 1.4 kb HindIII-NotI fragment (containing human IgG 1 Fc) from pIG-1 vector (24) was subcloned into the HindIII-NotI sites of the pSecTagB vector (Invitrogen) to construct the pSecBFc vector. PCR was performed using Expand polymerase (Roche Applied Science) and DEC-205 gene-specific primers (Table 1) to amplify fragments containing consecutive two DEC-205 extracellular domains (i.e. CTLD1/2, CTLD3/4, CTLD5/6, CTLD7/8 and CTLD9/10) from the L428 cDNA (12) . These fragments were cloned into the pSecBFc vector to generate pCTLD1/2-Ig, pCTLD3/4-Ig, pCTLD5/6-Ig, pCTLD7/ 8-Ig and pCTLD9/10-Ig, respectively. These constructs were transiently transfected into COS-7 cells using Fugene 6 (Roche Applied Science) and secreted DEC-205-Ig fusion proteins were purified using HiTrap protein A column chromatography (Amersham Pharmacia Biotec) and their purity was analyzed by SDS-PAGE.
Production of DEC-205 mAb
Splenocytes from Balb/C mice immunized with a mixture of DEC-205-Ig fusion proteins (CTLD1/2-Ig, CTLD3/4-Ig, CTLD5/ 6-Ig, CTLD7/8-Ig and CTLD9/10-Ig) were fused to mouse myeloma cell line NS-1 using a conventional polyethylene glycol fusion protocol. IgG-producing hybridomas were selected by dot blot analysis uing a HRP-conjugated goat anti-mouse IgG (c-chain-specific), and the signal detected by enhanced chemiluminescence (SuperSignal West Pico, Pierce, Rockford, IL, USA) on a AGFA Curix Ortho HT-G film (Burwood, VIC, Australia). IgG-producing hybridomas were further screened on the basis of reactivity to KM-H2 cells by flow cytometry, and their reactivities to DEC-205 were confirmed by ELISA against DEC-205-Ig fusion proteins and by immunoprecipitation analysis. The selected DEC-205 mAb producing hybridomas (MMRI-5, 6 and 7) were adapted to a serum-free medium (Hybridoma-SFM, Invitrogen) and the antibodies were purified by HiTrap protein G affinity column chromatography (Amersham Pharmacia). If required, the mAbs were conjugated with FITC (F/P =~6).
Characterization of DEC-205 mAb
For ELISA analysis, an ELISA plate coated with DEC-205-Ig fusion proteins or human immunoglobulins (Intragam, CSL, Australia) was incubated with DEC-205 mAbs, and their binding detected with HRP-conjugated goat anti-mouse IgG (c-chain-specific) and o-phenylenediamine (Sigma).
For immunoprecipitation analysis, PBMC were cell surface biotinylated using sulfo-NHS-LC-biotin (Pierce), and were lysed in the lysis buffer (1% Triton X-100, 0.25% sodium deoxycholate, 0.15 M NaCl, 50 mM Tris-HCl, pH 7.4 and 5 mM EDTA) containing a cocktail of protease inhibitors [Complete, Roche Applied Science, and 1 mM phenylmethylsulphonylfluoride (PMSF)] and the lysate was cleared by centrifugation at 20 000 3 g for 10 min at 4°C. The protein concentration was determined by bicinchoninic acid (BCA) assay (Pierce) using BSA as standards. The extract precleared with protein G Sepharose beads (Amersham Pharmacia) was subjected to immunoprecipitation with the DEC-205 mAbs and isotype control mAb 401.21 then protein G Sepharose beads. The protein G-bound proteins were fractionated using a 4-12% Nu-PAGE gel with MOPS buffer (Invitrogen). The proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane (PVDF-Plus, Osmonics, Westborough, MA, USA) and the signals detected with HRP-streptavidin (1:5000 dilution, Roche Applied Science) and enhanced chemiluminescence.
For DEC-205 mAb epitope mapping, KM-H2 cells were preincubated with unconjugated DEC-205 mAbs (10 lg ml ÿ1 ) on ice, washed and stained with 5 lg ml ÿ1 FITC-conjugated MMRI-7 or M335. The cells were subjected to flow cytometry.
Identification of DEC-205 protein by mass spectrometry
L428 cells (4 3 10 7 cells) were lysed with 1 ml of the lysis buffer with a cocktail of protease inhibitors and precleared with the isotype control mAb (401.21, 25 lg) and protein G Sepharose twice. The precleared lysate was subjected to immunoprecipitation with 25 lg MMRI-7 or 401.21 as described above and fractionated with a 4-12% Nu-PAGE gel under reducing conditions. The gel was stained with Coomassie Brilliant Blue R250 (CBB R250) and the MMRI-7-specific~200 kDa band was excised and subjected to mass spectrometry as described below.
The MMRI-7-specific band was reduced with 10 mM dithiothreitol (DTT) for 10 min and alkylated with 100 mM iodoacetamide for 1 h in the dark. The band was dehydrated with methanol and then washed three times in ultrapure water. The washed band was dried in a vacuum centrifuge (Speedvac) and rehydrated with 20 ll of a solution containing protein sequencing grade trypsin (2 lg ml ÿ1 , Promega) in 50 mM NaHCO 3 , pH 8. Digestion was allowed to proceed overnight at 37°C. The resultant peptides were extracted from the gel with 0.1% (v/v) formic acid and fractionated by C 18 HPLC using a 5-60% acetonitrile gradient in 0.1% formic acid. The column outflow was analyzed using a quadrupole time of flight tandem mass spectrometer (QTOF, ABI QStar) operating in independent data acquisition (IDA) mode. MASCOT (Matrix Science, Boston, MA, USA) was used to identify peptides and confirm protein identity (25) .
Biosensor assay
For biosensor analysis, DEC-205-Ig fusion proteins and human immunoglobulins (Intragam) were immobilized onto a CM5 sensor chip surface (BIACORE, Box Hill, VIC, Australia) using an amine coupling method to obtain 3000-4000 response units using a BIAcore 2000. For the binding kinetic experiments, the antibody concentrations ranged from 1 to 35 nM in six serial dilutions were passed over the sensor chip surface, and the results and kinetic parameters were evaluated using Global Analysis in the BIAevalutation software 3.1. (24) is underlined.
F(ab9) 2 purification
The F(ab9) 2 of MMRI-7 and 401.21 were purified using an ImmunoPure IgG 1 Fab and F(ab9) 2 Preparation Kit (Pierce). Briefly,~1 mg of mAb was digested with immobilized ficin in the presence of 1 mM cysteine at 37°C overnight and subjected to a protein A column chromatography to remove the Fc fraction and undigested mAb. The F(ab9) 2 was concentrated using a Centricon (YM30, Millipore, North Ryde, NSW, Australia) and their quality was assessed by SDS-PAGE.
DEC-205 expression analysis by flow cytometry
Blood was obtained from volunteer donors and ''inflammed'' palataine tonsils were obtained at routine tonsillectomy with appropriate informed consent, according to the Mater Hospital Human Research Ethical Committee guidelines. Buffy coat was obtained from Australian Red Cross. The flow cytometers were calibrated daily using fluorescent calibration beads (Calibrite, BD Bioscience). The data were analyzed using CellQuest (BD Bioscience 
Tissue staining
Tonsil frozen sections were fixed with acetone, blocked with 0.1% Tween 20, 1% Na-casein, 100 lg ml ÿ1 goat IgG in HEPES-buffered saline (0.15 M NaCl, 10 mM HEPES, pH 7.4) and incubated with 10 lg ml ÿ1 MMRI-7, MG38 or 401.21 mAb overnight at 4°C in a humidity chamber. After washing with 0.1% Tween 20 in PBS, the sections were incubated with Alexa Fluor 488-conjugated goat anti-mouse IgG (10 lg ml ÿ1 , Invitrogen), blocked with 10% mouse serum in PBS and further stained with PE-conjugated CD3, CD11c or an isotype control mAb. After the staining the sections were post-fixed with 4% PFA and mounted with 10% Mowiol (Calbiochem), 2.5% 1,4-diazabicyclo[2,2,2]octane, 50% glycerol in 100 mM Tris-HCl, pH 8.5, and observed under an epifluorescent microscope (Olympus BX61). The fluorescent images were captured using a cooled CCD camera (Evolution QEi, Media Cybernetics, Silver Spring, MD, USA) with an ImagePro software (Media Cybernetics).
Purification of human leukocytes
PBMC and tonsil mononuclear cells (MNC) were isolated over a Ficoll-Paque PLUS (Amersham Pharmacia) density gradient. To isolate pure T lymphocytes, B lymphocytes and NK cells and minimize contaminating cells (26) , the cells were firstly isolated using magnet-activated cell sorting (MACS) and subjected to fluorescent-activated cell sorting (FACS) using a FACSVantage (BD Bioscience) as described below. The purity of these leukocyte populations was >98%.
To isolate T lymphocytes, PBMC or tonsil MNC were incubated with the unconjugated anti-CD3 then goat antimouse-conjugated MACS beads (Militenyi Biotech) and subjected to an AutoMACS (Militenyi Biotech) to purify CD3 
Semiquantitative immunoprecipitation/western blot analysis
Five to ten million cells were lysed with 1 ml of the lysis buffer with a cocktail of protease inhibitors and the protein concentration in the lysate was determined by BCA assay. Serially diluted cell lysate (final protein concentration: 200, 100 and 50 lg ml ÿ1 ) was subjected to immunoprecipitation using the rabbit antiserum against DEC-205 CP peptide (anti-DEC-205 CP, 5 ll sample ÿ1 ) and protein A Sepharose as described previously (27) . The bound proteins were eluted with 2 3 Nu-PAGE sample buffer, fractionated in 4-12% Nu-PAGE gels in a non-reducing condition and transferred to a PVDF membrane. DEC-205 was detected by incubating the membrane with a mixture of DEC-205 mAbs (MMRI-7 and M335, 5 lg ml ÿ1 each) followed with HRP-conjugated goat anti-mouse IgG (c-chain-specific) and enhanced chemiluminescence as above.
Quantitative RT-PCR
Total RNA purified from FACS-purified cell populations (1.2 3 10 5 to 1 3 10 7 cells/preparation) using a Trizol (Invitrogen) was treated with DNase I to remove contaminating genomic DNA, and subjected to cDNA synthesis with a oligo dT 17 primer using Expand reverse transcriptase (Roche Applied Science).
For quantitative RT-PCR analysis, the cDNA was combined with DEC-205 gene-specific forward and reverse primers (see Table 1 ) and a SYBR green master mix (QuantiTect SYBR PCR kit, Qiagen, Clifton Hill, VIC, Australia), and subjected to real-time PCR using a Rotorgene 3000 thermal cycler (Corbett Research, Mortlake, NSW, Australia). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for normalization of cDNA input. The standard curves were generated using serially diluted gene-specific amplicons. The thermal cycling conditions were initial denaturation at 95°C for 15 
Results
Production of mAb against human DEC-205
We constructed a series of eukaryotic expression vectors for DEC-205-Ig fusion proteins, each of which contained consecutive pairs of human DEC-205 extracellular domains (Fig. 1A) . These Ig fusion proteins were transiently expressed in COS-7 cells, and the secreted fusion proteins were purified by protein A column chromatography (Fig. 1B) . Mice were immunized with a mixture of the human DEC-205-Ig fusion proteins and subsequent hybridomas screened by flow cytometry for binding to HRS cell line KM-H2 (DEC-205 mRNA + ) (27, 28) . We obtained three human DEC-205 mAbs termed MMRI-5, 6 and 7 (all IgG 1 isotype). These mAbs bind to the CTLD1/2-Ig fusion proteins by ELISA (Fig. 1C) , whereas the previously established DEC-205 mAbs M335 (28) and MG38 (21) bind to the CR/FN-Ig. Although the immunogen for M335 is unknown, the reactivity of MG38 to the CR/FN-Ig was consistent with the fact that a DEC-205 CR/FN fusion protein was used to produce the MG38 (21) . These data demonstrated that MMRI-5, 6 and 7 recognize epitopes within the CRD1/2, distinct from the epitopes within the CR/FN-Ig for M335 and MG38.
When subjected to immunoprecipitation analysis, M335 immunoprecipitated a single~200 kDa band from the lysate of cell surface-biotinylated PBMC specifically as previously described (Fig. 1D) (13, 28) . The MMRI-5, 6, 7 and MG38 immunoprecipitated the identical~200 kDa band. To investigate the identity of the~200 kDa band, the cell lysate of DEC-205 + cell line L428 (12, 27, 29) was subjected to a large scale immunoprecipitation with MMRI-7 and SDS-PAGE. The MMRI-7-specific~200 kDa band stained with CBB R250 (Fig. 1E) was excised, digested with sequencing grade trypsin and subjected to mass spectrometry for internal sequencing. MASCOT search of the mass spectrometry data identified 23 peptide sequences, all of which corresponded to DEC-205 protein sequence (Fig. 1F) . These data unequivocally confirmed that MMRI-7 recognized DEC-205 specifically.
To further characterize the DEC-205 mAbs, protein Gpurified MMRI-5, 6, 7 and M335 were conjugated with FITC and their reactivity to KM-H2 cells assessed at various mAb concentrations (Fig. 2A) . The reactivity of these FITCconjugated mAb to KM-H2 cell surface DEC-205 varied markedly (M335 > MMRI-7 > MMRI-6 > MMRI-5), and M335 and MMRI-7 reached a plateau at~5 lg ml
ÿ1
. Within the mAb concentration tested (up to 20 lg ml ÿ1 ), MMRI-6 did not reach to a plateau and MMRI-5 showed a very low reactivity to KM-H2 cell surface DEC-205. The biosensor analysis indicated that the K D for MMRI-6, 7 and M335 to their relevant DEC-205-Ig fusion proteins were 1.4 3 10 ÿ9 , 9.6 3 10 ÿ9 and 9.4 3 10 ÿ10 M, respectively (data not shown). We were not able to determine the K D for MMRI-5 probably due to its low affinity to non-denatured CTLD1/2-Ig fusion protein. The biosensor data were consistent with the FITC-DEC-205 mAb binding to KM-H2 cells. When KM-H2 cells were preincubated with unconjugated DEC-205 mAbs and stained with FITC-MMRI-7 (Fig. 2B) , unconjugated MMRI-7 inhibited~75% of FITC-MMRI-7 binding, whereas MMRI-5, 6 and MG38 had no effect, suggesting that the latter mAbs recognized distinct epitopes from that of MMRI-7. Interestingly, unconjugated M335 inhibited~25% of FITC-MMRI-7 binding, despite the epitope of M335 being within CR/FN-Ig (Fig. 1C) . Conversely, FITC-M335 binding to KM-H2 was inhibited by unconjugated M335 (~80%) and MMRI-7 (~20%), but not by MMRI-5, 6 or MG38. These data suggested that the epitopes for MMRI-7 and M335 were in close proximity on the structurally intact native molecule.
Human DEC-205 is expressed on DC in blood
We examined DEC-205 expression on the two main blood DC subsets, myeloid (lin
+ ) and plasmacytoid DC (lin ÿ DR + CD11c ÿ and BDCA2 + ) using FITC-conjugated MMRI-7 and MG38, fresh blood preparations and four-color flow cytometry (Fig. 3A) . Both mAb detected relatively high levels of DEC-205 expression on CD11c + Lin ÿ HLA-DR + myeloid blood DC, but in some donors the myeloid DC population was split into at least two subpopulations according to DEC-205 expression levels, which correlated with the HLA-DR expression levels (data not shown). Low levels of DEC-205 expression were detected on CD11c 
DEC-205 is expressed on T lymphocytes, B lymphocytes, NK cells and monocytes in PBMC
The analysis of DEC-205 expression on blood DC suggested that other leukocytes also expressed substantial levels of cell surface DEC-205. Therefore, we investigated the DEC-205 expression on other leukocytes, including T lymphocytes, B lymphocytes, NK cells and monocytes using FITC-conjugated MMRI-7 and MG38 by flow cytometry (Fig. 3B ). Cells were stained with DEC-205 mAbs combined with lineage antibodies and stringent gating strategies used to assess pure leukocyte populations for DEC-205 expression. This minimized the possible contamination of myeloid cells (monocytes and myeloid DC) and B lymphocytes expressing relatively high levels of DEC-205 as aggregates (26) . As shown in Fig. 3(B) , both MMRI-7 and MG38 detected cell surface DEC-205 on CD14 + CD19 ÿ DR + monocytes at relatively high levels. It was noted that DEC-205 expression on these cell types were similar to that on CD11c + myeloid blood
Human DEC-205 expression on leukocytes 861 (Fig. 4) . SDS-PAGE analysis confirmed that the MMRI-7 F(ab9) 2 preparation contained a major~100 kDa band under non-reducing conditions, which reduced to~25 kDa, indicating that the Fc portion of MMRI-7 had been removed (Fig. 4A) . The isotype control mAb SDS-PAGE profile included a slightly smaller band upon reduction, which was likely derived from an excess ficin digestion. The F(ab9) 2 confirmed that the staining of the B lymphocytes, NK cells and monocytes for surface DEC-205 and established that it was not due to the non-specific MMRI-7 binding to FccR expressed on these cells (Fig. 4B) . The majority of T lymphocytes were also stained with MMRI-7 F(ab9) 2 , consistent with the results obtained with the intact MMRI-7. The MMRI-7 F(ab9) 2 staining on CD11c + myeloid BDC and CD11c -/BDCA2 + plasmacytoid BDC was essentially consistent with the staining obtained with the intact MMRI-7 (Fig. 3) . 
DEC-205 expression in tonsil tissue
We further investigated the DEC-205 expression on tonsilderived MNC using FITC-conjugated MMRI-7 by flow cytometry and immunofluorescent microscopy (Fig. 5) . MMRI-7 indicated higher levels of DEC-205 expression on tonsil myeloid (Lin ÿ DR + CD11c + ) and plasmacytoid DC (BDCA2 + ) compared with the BDC subsets (Fig. 5A) Staining with MMRI-7 revealed that the strongly DEC-205 + cells were scattered in the T cell area and the B cell area throughout the tonsil, but at higher density in the T cell area. These DEC-205 + cells were large cells with dendritic morphology and also strongly CD11c + , suggesting that they were myeloid DC. A similar DEC-205 staining pattern was also obtained with MG38. There was also weak DEC-205 + staining present on both T and B lymphocytes, but background issues meant this was better determined by flow cytometry.
Semiquantitative immunoprecipitation/western blot analysis detects a 200 kDa DEC-205 band in FACS-purified leukocyte cell lysate As further confirmation of the presence of DEC-205 on the various leukocyte populations, we performed semiquantitative immunoprecipitation/western blot analysis to detect DEC-205 protein in monocyte-derived DC (MoDC), macrophage and lineage-positive cell preparations. The serially diluted cell lysate of highly purified leukocytes was subjected to immunoprecipitation with the rabbit anti-DEC-205 CP antibody and protein A agarose. The immunoprecipitated proteins were fractionated on SDS-PAGE and subjected to western blot analysis for DEC-205 (Fig. 6) (27) . The DEC-205 expressing cell line L428 was used as a positive control for immunoprecipitation and to normalize the two PAGE gels required for the analysis.
We detected a single~200 kDa band in all cell preparations tested, including T lymphocytes, B lymphocytes, NK cells, monocytes, macrophages and MoDC. Detection of the DEC-205 band was specific because there was no band in L428 lysate immunoprecipitated with the pre-immune rabbit serum (lane 2). Interestingly, the similar amount of DEC-205 protein (less than two-fold difference) was detected in the nonactivated cell lysate tested when normalized by cellular proteins. We also detected a 180 kDa band in cell lysates from T lymphocytes, B lymphocytes, NK cells and monocytes, but not in other cell types. The nature of this 180 kDa band is unknown but it may correspond to a splice variant of DEC-205 mRNA we described recently, encoding a truncated CTLD10 (27) . Activation of macrophages and MoDC using LPS increased the~200 kDa band markedly, LPS-activated MoDC, in particular, increased DEC-205 protein expression at least 30-fold. Quantitative RT-PCR detects DEC-205 mRNA in DC, lymphocytes, monocytes, granulocytes and macrophages
To investigate whether the surface DEC-205 was expressed by wide range of leukocyte populations endogenously or was simply adsorbed on their surface, we performed quantitative RT-PCR on DC, granulocytes, macrophages, T lymphocytes, B lymphocytes and NK cells purified by flow cytometry (purity >98%) (Fig. 7) . GAPDH was used to normalize cDNA input.
We detected relatively high levels of DEC-205 mRNA in MoDC, blood DC, macrophages and granulocytes as expected. The mRNA levels in the MoDC increased markedly upon maturation of MoDC by LPS as shown previously (23) . Despite relatively high levels of cell surface DEC-205 expression (Figs. 3 and 4) , both B lymphocytes and monocytes express comparatively low levels of DEC-205 mRNA. On the other hand, T lymphocytes and NK cells, which express low levels of cell surface DEC-205 (Figs. 3 and 4) , expressed moderate levels of DEC-205 mRNA. Overall, the amount of DEC-205 mRNA levels in these leukocyte populations correlated to the DEC-205 protein levels normalized by cellular protein (see Fig. 6 ), suggesting that DEC-205 expression is transcriptionally regulated.
Taken together, these data demonstrate that human DEC-205 is expressed not only by the expected cell types based on the published mouse DEC-205 expression (i.e. DC, B lymphocytes and T lymphocytes) but also by monocytes, macrophages and NK cells.
Discussion
We developed a series of mAbs against human DEC-205 and performed a comprehensive analysis of DEC-205 expression on human leukocytes. This established that DEC-205 is expressed on many more leukocyte populations, including DC, B lymphocytes, T lymphocytes, NK cells and monocytes, at higher levels than had been hitherto realized.
The rat mAb NLDC-145, which first identified mouse DEC-205, has been used extensively to identify DC based on the original description of its reactivity as being restricted to interdigitating DC, LC and thymic epithelia (6) . Thus, it has been used to define murine DC subsets and this apparent specificity exploited in functional studies (11, 16) . It has been assumed that the distribution of the human ortholog might be similarly restricted. The high affinity rabbit polyclonal antibody against mouse DEC-205, however, revealed that mouse DEC-205 was also expressed on Gr-1 + granulocytes, Thy-1 + T lymphocytes, B220 + B lymphocytes and thioglycollate-elicited peritoneal macrophages but their expression levels were much lower (>1 log) than those on DC. Mac-1 + Gr-1 ÿ monocytes did not express DEC-205 (30) . The polyclonal antibody also detected DEC-205 in mouse non-lymphatic tissues, including capillary endothelial cells in brain, the stroma of bone marrow and the epithelial cells in pulmonary airways and gastrointestinal tract (31) . Therefore, mouse DEC-205 is predominantly expressed by DC.
Several mAbs against human DEC-205 have been described to date, including MR6 (13, 32) , M335 (28) and MG38 (21) . In addition to these, we developed a series of DEC-205 mAb termed MMRI-5, 6 and 7. These DEC-205 mAb recognized the CRD1/2-Ig (Fig. 1C) and immunoprecipitated a single~200 kDa band (Fig. 1D) . Furthermore, we subjected the~200 kDa band immunoprecipitated with MMRI-7 to internal sequencing by mass spectrometry and confirmed its identity as DEC-205 (Fig. 1E and F) . We utilized two mAbs MG38 and MMRI-7, which recognize distinct DEC-205 domains (CR-FN domain for MG38 and CTLD1/2 domain for MMRI-7) (Fig. 1C) , to analyze DEC-205 expression in man (Figs. 3 and 4) . Further, expression of DEC-205 in the human leukocyte populations was confirmed by semiquantitative immunoprecipitation/western blot analysis (Fig. 6 ) and DEC-205-specific quantitative RT-PCR (Fig. 7) . Our results showed that DEC-205 was expressed at high levels on myeloid DC and monocytes, at moderate levels on B lymphocytes and at low levels on NK cells, plasmacytoid DC and T leukocytes, indicating that human DEC-205 expression on leukocytes differed from the mouse ortholog.
DEC-205 has been proposed to be an antigen uptake/ processing receptor on DC because (a) DEC-205 is structurally similar to MMR, a prototype antigen uptake receptor expressed on macrophages and MoDC (33), (b) DEC-205 is highly expressed on DC (5, 30) and (c) DEC-205 CP contains an acidic triad motif for efficient targeting of late endosomes and antigen processing (15) . In fact, it was shown recently that chemically or genetically modified NLDC-145 conjugated with test antigens can target lymph node DC when intradermally injected, and elicit antigen-specific CD4 + and CD8 + T lymphocyte responses with high efficiency (11, 16) . Although DEC-205 appears to be an attractive target to load antigens into DC and the mouse data argue that there is a functional specificity, our results suggest that clinical studies will need to take account of its broad tissue distribution and the affinity of any candidate mAb-based therapeutics. Ultimately, anti-human DEC-205 clinical trials will be required to test functional DC targeting specificity.
